Inspira ends ATM and SEPA equity facilities

Inspira Technologies Oxy B.H.N.

Rhea-AI Filing Summary

Inspira Technologies Oxy B.H.N. Ltd. submitted a report describing the termination of two equity financing arrangements: its sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd. The company states that no obligations remain and no further advances will be made under either facility. Management explains that ending these facilities aligns with its goal of maintaining a disciplined capital structure as it prepares for its next strategic phase.

The report also highlights that Inspira is a commercial-stage medical device company focused on advanced respiratory support and blood monitoring, including its FDA-cleared INSPIRA ART100 system for cardiopulmonary bypass in the U.S., ECMO-related uses outside the U.S., and development of the INSPIRA ART500 and HYLA blood sensor platform.

Insights

Capital structure and medtech strategy analyst

Inspira ends two equity facilities, signaling a shift in financing strategy without detailing new funding plans.

Inspira Technologies has terminated its at-the-market sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd., with no remaining obligations or future advances. This removes two previously available equity financing channels.

The company frames this choice as part of a “disciplined capital structure” and preparation for a “next strategic phase.” The filing does not outline replacement funding sources or detailed initiatives, so the direct financial impact depends on its cash position and alternative capital options, which are not discussed here.

Alongside this, the company reiterates progress in its respiratory support and blood monitoring portfolio, including the FDA-cleared INSPIRA ART100, the in-development INSPIRA ART500, and HYLA. Future disclosures in annual or periodic reports may clarify how strategy and funding align around these products.

Key Terms

ATM, Standby Equity Purchase Agreement, cardiopulmonary bypass, ECMO (Extracorporeal Membrane Oxygenation), +1 more

5 terms

ATM financial

"Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase"

Standby Equity Purchase Agreement financial

"its Standby Equity Purchase Agreement with YA II PN, Ltd, dated December 12, 2025"

A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.

cardiopulmonary bypass medical

"INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S."

Cardiopulmonary bypass is a medical procedure where a machine temporarily takes over the heart and lungs during major surgery, circulating and oxygenating the blood so surgeons can operate on a still, blood-free heart. Investors care because the technique drives demand for specialized equipment, disposables, training and hospital services, and changes in safety, regulation, procedure volumes or technology can materially affect the revenues and costs of device makers and healthcare providers.

ECMO (Extracorporeal Membrane Oxygenation) medical

"and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S"

FDA-cleared regulatory

"The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Inspira Technologies (IINN) announce in this Form 6-K?

Inspira Technologies reported it has terminated its ATM sales agreement with A.G.P./Alliance Global Partners and its Standby Equity Purchase Agreement with YA II PN, Ltd., leaving no remaining obligations or further advances under either equity financing facility.

Why did Inspira Technologies (IINN) terminate its ATM and SEPA equity facilities?

The company states that ending the ATM and Standby Equity Purchase Agreement reflects its commitment to a disciplined capital structure as it prepares for its next strategic phase, implying a deliberate shift in how it plans to manage financing and future growth initiatives.

Does Inspira Technologies still have obligations under the terminated equity agreements?

No. Inspira Technologies notes it delivered formal written notices to terminate both financing facilities and specifically states there are no outstanding obligations and no further advances to be made under either agreement by any of the involved parties.

What kind of business is Inspira Technologies (IINN) and what products does it offer?

Inspira Technologies is a commercial-stage medical device company focused on advanced respiratory support and real-time blood monitoring. It highlights its FDA-cleared INSPIRA ART100 system, under development INSPIRA ART500 oxygenation platform, and HYLA, a proprietary continuous, non-invasive blood sensor technology.

How does Inspira describe its strategic position after terminating these financing facilities?

The company says the decision supports a disciplined capital structure and strategic streamlining of operations. It describes itself as increasingly positioned as an attractive platform within the life-support and MedTech landscape, supported by cleared products and a growing intellectual property portfolio.

Where can investors find more risk information about Inspira Technologies (IINN)?

The company points investors to the “Risk Factors” section in its annual report on Form 20-F for the year ended December 31, 2025, which is available on the U.S. Securities and Exchange Commission’s website, providing detailed discussion of key business and regulatory risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 08:15 AM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of March 2026 (Report No. 3)

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F      ☐ Form 40-F

CONTENTS

On March 31, 2026, Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) issued a press release titled “Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K (this “Report”).

This Report is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308 and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565, 333-290162 and 333-292592), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on March 31, 2026, titled “Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase.”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inspira Technologies Oxy B.H.N. Ltd.
Date: March 31, 2026	By:	/s/ Dagi Ben-Noon
		Name:	Dagi Ben-Noon
		Title:	Chief Executive Officer

2

Exhibit 99.1

 

Inspira Technologies Terminates ATM and SEPA Equity Facilities to Prepare for Next Strategic Phase

RA’ANANA, Israel, March 31, 2026 -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (“Inspira” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the termination of its sales agreement with A.G.P./Alliance Global Partners, dated February 17, 2026, and its Standby Equity Purchase Agreement with YA II PN, Ltd, dated December 12, 2025.

The Company has delivered formal written notices to terminate these financing facilities, with no outstanding obligations or further advances to be made under either agreement by either of the parties to the respective agreements.

The decision reflects the Company’s commitment to maintaining a disciplined capital structure, as it prepares for its next strategic phase.

About Inspira Technologies

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statement Disclaimer

This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its expectations regarding its strategic direction and upcoming initiatives, its intention to maintain a disciplined capital structure, preparation for its next strategic phase, and the timing and content of any future updates regarding its strategic plans. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

Investor Relations Contact
Arx Investor Relations
North American Equities Desk
inspira@arxhq.com

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 7.5 KB
• EX-99 GRAPHIC 6.1 KB